Stocktoria
SAB Biotherapeutics, Inc. SABS
SAB Biotherapeutics, Inc. (SABS) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.523 |
| Retained earnings / assets | -0.642 |
| EBIT / assets | -0.283 |
| Equity / liabilities | 7.107 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | 3/9 | 6.9 | 21.9 | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
FAQ
Is SABS financially healthy?
SAB Biotherapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SABS pay a dividend?
No, SAB Biotherapeutics, Inc. does not currently pay a dividend.
How profitable is SABS?
In FY2025, SAB Biotherapeutics, Inc. had a return on equity of 8.8%.
What is SABS's P/E ratio?
SAB Biotherapeutics, Inc.'s trailing price-to-earnings (P/E) ratio is about 21.9×, based on its latest annual earnings.
What is the analyst price target for SABS?
The average Wall-Street price target for SAB Biotherapeutics, Inc. is $11.18, about 194.3% above the recent price, from 11 analysts (consensus: strong buy).
Is SABS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SAB Biotherapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone, a P/E of about 21.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.